JP2021501143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501143A5 JP2021501143A5 JP2020522999A JP2020522999A JP2021501143A5 JP 2021501143 A5 JP2021501143 A5 JP 2021501143A5 JP 2020522999 A JP2020522999 A JP 2020522999A JP 2020522999 A JP2020522999 A JP 2020522999A JP 2021501143 A5 JP2021501143 A5 JP 2021501143A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dosage form
- polyglutamic acid
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 229920002643 polyglutamic acid Polymers 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 206010059866 Drug resistance Diseases 0.000 claims 5
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical class [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 5
- 239000008297 liquid dosage form Substances 0.000 claims 5
- 230000002018 overexpression Effects 0.000 claims 4
- 239000007909 solid dosage form Substances 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 claims 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 2
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 claims 2
- 108010020346 Polyglutamic Acid Proteins 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- -1 minitabs Substances 0.000 claims 2
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 claims 2
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 claims 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000010408 film Substances 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 239000007897 gelcap Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000006193 liquid solution Substances 0.000 claims 1
- 239000006194 liquid suspension Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 239000000668 oral spray Substances 0.000 claims 1
- 229940041678 oral spray Drugs 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 229960003330 pentetic acid Drugs 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000005460 tetrahydrofolate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201708886R | 2017-10-30 | ||
| SG10201708886RA SG10201708886RA (en) | 2017-10-30 | 2017-10-30 | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER |
| PCT/SG2018/050544 WO2019088919A1 (en) | 2017-10-30 | 2018-10-29 | Compositions comprising alpha-polyglutamic acid-zinc for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501143A JP2021501143A (ja) | 2021-01-14 |
| JP2021501143A5 true JP2021501143A5 (enExample) | 2021-11-25 |
| JP7352541B2 JP7352541B2 (ja) | 2023-09-28 |
Family
ID=64184154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522999A Active JP7352541B2 (ja) | 2017-10-30 | 2018-10-29 | がんを処置するためのアルファ－ポリグルタミン酸－亜鉛を含む組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200254013A1 (enExample) |
| EP (1) | EP3703708A1 (enExample) |
| JP (1) | JP7352541B2 (enExample) |
| KR (1) | KR102725852B1 (enExample) |
| CN (1) | CN111542328A (enExample) |
| SG (2) | SG10201708886RA (enExample) |
| WO (1) | WO2019088919A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| CN117377497A (zh) | 2021-03-18 | 2024-01-09 | 翟伦尼克斯私人有限公司 | 药物聚合物缀合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| AU2291001A (en) * | 1999-12-23 | 2001-07-03 | Emory University | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
| US20020061599A1 (en) * | 1999-12-30 | 2002-05-23 | Elling Christian E. | Method of identifying ligands of biological target molecules |
| WO2003061598A2 (en) * | 2002-01-25 | 2003-07-31 | The University Of Georgia Research Foundation, Inc. | Solenopsin a, b and analogs as novel angiogenesis inhibitors |
| EP1890537B1 (en) * | 2005-06-07 | 2012-08-08 | Yale University | Methods of treating cancer and other conditions or disease states using lfmau and ldt |
| JPWO2007043606A1 (ja) * | 2005-10-12 | 2009-04-16 | 株式会社ジェノラックＢｌ | アニオン性ポリアミノ酸／金属複合体からなる抗糖尿病薬剤 |
| CN101674852A (zh) * | 2007-04-10 | 2010-03-17 | 日东电工株式会社 | 多功能聚谷氨酸盐药物载体 |
| CN101795677B (zh) * | 2007-05-09 | 2012-11-14 | 沙路特里亚制药有限责任公司 | 用于治疗炎性病症的螺环化合物 |
| WO2008141110A2 (en) | 2007-05-09 | 2008-11-20 | Nitto Denko Corporation | Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
| US20110117210A1 (en) * | 2009-11-17 | 2011-05-19 | Andrey Ugolkov | Therapeutic treatment of human cancers using simple salts of zinc |
| US9132098B2 (en) | 2013-03-28 | 2015-09-15 | Bbs Nanotechnology Ltd. | Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it |
| CN105143242A (zh) | 2013-04-26 | 2015-12-09 | 日东电工株式会社 | 大规模制备聚(谷氨酰基-谷氨酸盐)偶联物的方法 |
| SG10201609131YA (en) * | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
-
2017
- 2017-10-30 SG SG10201708886RA patent/SG10201708886RA/en unknown
-
2018
- 2018-10-29 WO PCT/SG2018/050544 patent/WO2019088919A1/en not_active Ceased
- 2018-10-29 JP JP2020522999A patent/JP7352541B2/ja active Active
- 2018-10-29 SG SG11202003967PA patent/SG11202003967PA/en unknown
- 2018-10-29 US US16/760,264 patent/US20200254013A1/en not_active Abandoned
- 2018-10-29 KR KR1020207014679A patent/KR102725852B1/ko active Active
- 2018-10-29 EP EP18799880.2A patent/EP3703708A1/en active Pending
- 2018-10-29 CN CN201880084765.4A patent/CN111542328A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534330A5 (enExample) | ||
| US20230190683A1 (en) | Methods for the treatment of cysteamine sensitive disorders | |
| AU2017235631B2 (en) | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders | |
| JP2020519295A5 (enExample) | ||
| HRP20180375T1 (hr) | Derivati hidrobebenzamida kao inhibitori hsp90 | |
| CN103842330B (zh) | 抗炎的取代的环丁烯二酮化合物的胆碱盐 | |
| HRP20130961T1 (hr) | Kombinacije za tretman raka | |
| JPS60208913A (ja) | 高めた無痛覚を与える製薬製品 | |
| CN103917231A (zh) | 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途 | |
| JP2017537899A5 (enExample) | ||
| JP2009215293A5 (enExample) | ||
| CN108601952B (zh) | 雷公藤内酯的葡萄糖缀合物、类似物及其用途 | |
| JP2013527224A5 (enExample) | ||
| JP2012519201A5 (enExample) | ||
| JP2008533127A5 (enExample) | ||
| JP2017512194A5 (enExample) | ||
| JP2021501143A5 (enExample) | ||
| JP7083835B2 (ja) | 亜鉛－γ－ＰＧＡ組成物およびがんを処置するための方法 | |
| JP2009517411A5 (enExample) | ||
| JP2013536243A5 (enExample) | ||
| CN118946371A (zh) | 靶向psma的放射性药物和检查点抑制剂的组合疗法 | |
| ES2197867T3 (es) | Producto granulado con alto contenido en l-carnitina o alcanoil l-carnitina particularmente apropiado para la produccion de comprimidos por compresion directa. | |
| RU2016116915A (ru) | Комбинация | |
| JP7357386B2 (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| RU2003125876A (ru) | Лекарственная композиция, включающая диклофенак и орнопростил |